HLA-A3 increases and HLA-DR1 decreases the risk of acute graft-versus-host disease after HLA-matched sibling bone marrow transplantation for chronic myelogenous leukaemia

British Journal of Haematology

Volumn 114, Issue 1, 2001, Pages 36-41

  Clark, Richard E ^a,h   Hermans, Jo ^b   Madrigal, Alejandro ^c   Nachbaur, David ^d   Kropshofer, Gabriele ^d   Gratwohl, Alois ^e   Apperley, Jane ^f   Niederwieser, Dietger ^g  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

^f HAMMERSMITH HOSPITAL   (United Kingdom)

^g UNIVERSITY OF LEIPZIG   (Germany)

^h ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Acute GVHD; BCR ABL; CML; HLA; MHC

Indexed keywords

BCR ABL PROTEIN; HLA A3 ANTIGEN; HLA DR1 ANTIGEN;

ADOLESCENT; ADULT; ALLELE; ALLOIMMUNITY; ARTICLE; BONE MARROW TRANSPLANTATION; CHILD; CHRONIC MYELOID LEUKEMIA; DISEASE ASSOCIATION; FEMALE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; PRIORITY JOURNAL; RELAPSE; RISK; SURVIVAL;

ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY TESTING; HLA-A3 ANTIGEN; HLA-DR1 ANTIGEN; HUMANS; INFANT; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0034928766     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.02897.x     Document Type: Article

References (32)

1. Graft-versus-leukaemia: Understanding and using the alloimmune response to treat haematologicaI malignancies
2. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules
3. Specific human cellular immunity to bcr-abl oncogene-derived peptides
4. Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNT genes and HLA-DR alleles. Relevance for inflammatory bowel disease
5. Identification of a graft versus host disease-associated human minor histocompatibility antigen
6. Graft-versus-host disease
7. Risk factors for acute graft-versus-host disease
8. The biochemistry and cell biology of antigen processing and presentation
9. The graft-vs.-host reaction in man. Genetics, clinical features, and immunopathology
10. The regulatory role of HLA-DRw6 in renal transplantation
11. Increased serum levels of tumor-necrosis-factor alpha (TNF-alpha) precede major complications of bone marrow transplantation
12. Supply and transport of peptides presented by class I MHC molecules
13. Tumour necrosis factor alpha in autoimmunity: Pretty girl or old witch?
14. + T cell responses
15. Prevention and treatment of acute graft-versus-host disease: The old and the new
16. Maternally transmitted histocompatibility antigen of mice: A hydrophobic peptide of a mitochondrially encoded protein
17. The three-dimensional structure of peptide-MHC complexes
18. A retrospective analysis of therapy of acute graft-versus-host disease: Initial treatment
19. Polymorphic structure of the tumour necrosis factor (TNF) locus: An NcoI polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF-beta production
20. Feasibility of immunotherapy of relapsed leukemia with ex vivo generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens
21. Correlation of minor histocompatibility antigen-specific cytotoxic T lymphocytes with graft-versus-host disease status and analyses of tissue distribution of their target antigens
22. HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukemia
23. HLA-DR4 is associated with a diminished risk of the development of chronic myeloid leukemia (CML)
24. Prevention of graft-versus-host disease by peptides binding to class II major histocompatibility complex molecules
25. Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs
26. The MHC influences acute graft versus host disease in MHC matched adults undergoing allogeneic bone marrow transplantation
27. Nuclear myxovirus-resistance protein Mx is a minor histocompatibility antigen
28. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment
29. Association between HLA-B antigens and acute graft-versus-host disease
30. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia
31. Bonemarrow transplantation
32. Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation